Personalis, Inc. (NASDAQ:PSNL) Holdings Boosted by ARK Investment Management LLC

ARK Investment Management LLC raised its position in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 11.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,085,523 shares of the company's stock after purchasing an additional 723,637 shares during the quarter. ARK Investment Management LLC owned about 13.64% of Personalis worth $38,120,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in PSNL. GSA Capital Partners LLP increased its stake in shares of Personalis by 6.2% in the first quarter. GSA Capital Partners LLP now owns 420,141 shares of the company's stock valued at $626,000 after purchasing an additional 24,498 shares during the period. Acadian Asset Management LLC increased its stake in shares of Personalis by 90.7% during the first quarter. Acadian Asset Management LLC now owns 991,828 shares of the company's stock valued at $1,476,000 after acquiring an additional 471,646 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Personalis by 58.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 95,000 shares of the company's stock valued at $142,000 after acquiring an additional 34,900 shares during the period. Public Employees Retirement System of Ohio acquired a new position in shares of Personalis during the first quarter valued at approximately $29,000. Finally, Jacobs Levy Equity Management Inc. increased its stake in shares of Personalis by 144.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 821,657 shares of the company's stock valued at $1,224,000 after acquiring an additional 485,822 shares during the period. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Trading Up 5.3 %

Personalis stock traded up $0.23 during mid-day trading on Friday, hitting $4.55. The company's stock had a trading volume of 1,264,287 shares, compared to its average volume of 717,108. Personalis, Inc. has a twelve month low of $0.89 and a twelve month high of $7.20. The stock's fifty day moving average price is $5.15 and its two-hundred day moving average price is $3.32.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.34) by $0.10. Personalis had a negative net margin of 104.52% and a negative return on equity of 72.35%. The firm had revenue of $22.58 million during the quarter, compared to analyst estimates of $19.81 million. During the same quarter last year, the business posted ($0.50) EPS. On average, research analysts predict that Personalis, Inc. will post -1.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. HC Wainwright raised their price objective on shares of Personalis from $7.50 to $9.00 and gave the company a "buy" rating in a research note on Monday, August 19th. Needham & Company LLC reiterated a "buy" rating and set a $7.25 price objective on shares of Personalis in a research note on Thursday. Finally, BTIG Research raised their price objective on shares of Personalis from $5.50 to $7.00 and gave the company a "buy" rating in a research note on Friday, August 16th.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.